Structure−Activity Relationship of Quinoline Derivatives as Potent and Selective α2C-Adrenoceptor Antagonists
摘要:
Starting from two acridine compounds identified in a high-throughput screening campaign (1 and 2, Table 1), a series of 4-aminoquinolines was synthesized and tested for their properties on the human alpha(2)-adrenoceptor subtypes (alpha(2A), alpha(2B), and alpha(2C.)). A number of compounds with good antagonist potencies against the alpha(2C)-adrenoceptor and excellent subtype selectivities over the other two subtypes were discovered. For example, (R)-{4-[4-(3,4-dimethylpiperazin-1-yl) phenylamino] quinolin- 3- yl} methanol 6j had an antagonist potency of 8.5 nM against, and a subtype selectivity of more than 200-fold for, the alpha(2C)-adrenoceptor. Investigation of the structure-activity relationship identified a number of structural features, the most critical of which was an absolute need for a substituent in the 3-position of the quinoline ring. The 3-position on the piperazine ring was also found to play an appreciable role, as substitutions in that position exerted a significant and stereospecific beneficial effect on the alpha(2C)-adrenoceptor affinity and potency. Replacing the piperazine ring proved difficult, with 1,4-diazepanes representing the only viable alternative.
Structure−Activity Relationship of Quinoline Derivatives as Potent and Selective α2C-Adrenoceptor Antagonists
摘要:
Starting from two acridine compounds identified in a high-throughput screening campaign (1 and 2, Table 1), a series of 4-aminoquinolines was synthesized and tested for their properties on the human alpha(2)-adrenoceptor subtypes (alpha(2A), alpha(2B), and alpha(2C.)). A number of compounds with good antagonist potencies against the alpha(2C)-adrenoceptor and excellent subtype selectivities over the other two subtypes were discovered. For example, (R)-{4-[4-(3,4-dimethylpiperazin-1-yl) phenylamino] quinolin- 3- yl} methanol 6j had an antagonist potency of 8.5 nM against, and a subtype selectivity of more than 200-fold for, the alpha(2C)-adrenoceptor. Investigation of the structure-activity relationship identified a number of structural features, the most critical of which was an absolute need for a substituent in the 3-position of the quinoline ring. The 3-position on the piperazine ring was also found to play an appreciable role, as substitutions in that position exerted a significant and stereospecific beneficial effect on the alpha(2C)-adrenoceptor affinity and potency. Replacing the piperazine ring proved difficult, with 1,4-diazepanes representing the only viable alternative.
[EN] PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS<br/>[FR] PYRIMIDOPYRIMIDINONES UTILES COMME INHIBITEURS DE LA WEE-1 KINASE
申请人:ALMAC DISCOVERY LTD
公开号:WO2015092431A1
公开(公告)日:2015-06-25
The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.
TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES
申请人:Galapagos N.V.
公开号:EP2086540A1
公开(公告)日:2009-08-12
PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS
申请人:Almac Discovery Limited
公开号:EP3083625A1
公开(公告)日:2016-10-26
US9850247B2
申请人:——
公开号:US9850247B2
公开(公告)日:2017-12-26
[EN] TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDINE POUR LE TRAITEMENT DE MALADIES DÉGÉNÉRATIVES ET INFLAMMATOIRES
申请人:GALAPAGOS NV
公开号:WO2008065198A1
公开(公告)日:2008-06-05
[EN] Novel triazolopyridine compounds are disclosed that have a formula represented by Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non- limiting example, ECM degradation, joint degradation and/or inflammation, and others. [FR] L'invention concerne de nouveaux composés de triazolopyridine représentéw par la formule suivante : (I). Ces composés peuvent être préparés sous forme de compositions pharmaceutiques, et être utilisés pour la prévention et le traitement de divers troubles chez les mammifères, y compris l'homme, notamment, à titre d'exemples sans valeur limitative, la dégradation de la matrice extracellulaire, la dégradation des articulations et/ou les inflammations, etc.